Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BMO Capital Maintains Outperform on Nuvei, Lowers Price Target to C$90

BMO Capital Maintains Outperform on Nuvei, Lowers Price Target to C$90

BMO Capital analyst James Fotheringham maintains Nuvei (TSX:NVEI) with a Outperform and lowers the price target from C$93 to C$90.

byBenzinga Newsdesk

March 9, 2023

1 minute read

BMO Capital analyst James Fotheringham maintains Nuvei (TSX:NVEI) with a Outperform and lowers the price target from C$93 to C$90.

Raytheon Technologies Secures $237M Counter-UAS Contract

By Akanksha Bakshi

April 19, 9:45 AM

Raytheon Technologies Corporation (NYSE:RTX) has secured a $237 million U.S. Army contract for Ku-band Radio Frequency Sensors (KuRFS) and Coyote effectors…

NOC

Thermo Fisher Reportedly Close To Buying UK-Based Diagnostic Firm For $2.3B

By Vandana Singh

October 31, 6:13 AM

Thermo Fisher Scientific Inc (NYSE: TMO) is close to acquiring UK-based diagnostic firm Binding Site from private equity fund Nordic Capital.

TMO

This Pot Giant Rebrands Popular Brand, Launches 50mg THC Edibles

By Vuk Zdinjak

July 10, 9:02 AM

Curaleaf Holdings, Inc. (OTCQX: CURLF) (CSE:CURA) unveiled the strategic national rebrand of its Select cannabis lifestyle brand across 15 U.S. states.

CSE:CURA

DOJ Urges Judge To Exclude Sam Bankman-Fried’s Anthropic AI Investment Valuation In Trial

By Murtuza Merchant

October 9, 2:14 PM

The U.S.

$FTT

BMO Capital Maintains Outperform on Nuvei, Lowers Price Target to C$90

Related Posts

Raytheon Technologies Secures $237M Counter-UAS Contract

Thermo Fisher Reportedly Close To Buying UK-Based Diagnostic Firm For $2.3B

This Pot Giant Rebrands Popular Brand, Launches 50mg THC Edibles

DOJ Urges Judge To Exclude Sam Bankman-Fried’s Anthropic AI Investment Valuation In Trial